 |
| Members of the WBU delegation at WIPO SCCR 22 |
June 16, 10 am: There are good news and less good news to report from Geneva. While overall, things have moved in positive directions, with the US and the EU engaged in very constructive negotiations with Brazil and other treaty sponsors, there are still many frustrations. Continue Reading
Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.
These are the data:
2010 Global R&D by all private companies: – $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
http://report.nih.gov/investigators_and_trainees/acd_bwf/pdf/Phrma_Industry_Profile_2011.pdf
2010 Global sales – $856 billion
Continue Reading
This is a report from the FDA on 2011 new molecular entities (NMEs) approvals, through June 6, 2011. The total number of FDA approvals during that same period was 150. So far, 16 NMEs have been approved in five months, a sharp increase in approvals over the same period 2010.
6 NMEs NDAs were considered priorities
8 NDAs that were considered standard approvals
2 BLA (biologic products) that were not classified.
On Thursday, May 26, 2011, Senator Bernie Sanders (I-VT) introduced two bills in the United States Senate that would de-link R&D costs from drug prices. The bill names and numbers are as follows:
24 May 2011
NGO letter on Conflicts of Interest, Future Financing, Reform and governance of the WHO.
Dear Members of the Executive Board,
WIPO
World Intellectual Property OrganizationSCP/16/8 PROV.
ORIGINAL: ENGLISH
DATE: MAY 20, 2011Standing Committee on the Law of Patents
Sixteenth Session
Geneva, May 16 to 20, 2011SUMMARY BY THE CHAIR
Agenda Item 1: Opening of the session
1. The sixteenth of the Standing Committee on the Law of Patents (SCP) was opened by Mr. James Pooley, Deputy Director General, who welcomed the participants. Mr. Philippe Baechtold (WIPO) acted as Secretary.
Continue ReadingUSPTO statement at WIPO side event on Medicines Patent Pool
This is the statement that was delivered by Karin L. Ferriter (from USPTO and USTR), at a UNITAID side event on the Medicines Patent Pool, during a break of the WIPO Standing Committee on the Law of Patents.
Statement on Medicines Patent Pool Side EventNGO Statement on WHO governance and the Management of Conflicts of Interest and the Future of Financing for WHO
NGO Statement on WHO governance and the Management of Conflicts of Interest and the Future of Financing for WHO.
May 18, 2011
We write to express our concerns about governance of the World Health Organization (WHO) and other public health bodies, as regards the management of conflicts of interest.